Jul. 17, 2013
On July 17, 2013 Sihuan Pharmaceutical Holdings announced that its Anaprazole Sodium, a Category 1.1 new drug, received the approval for clinical studies from the CFDA. Anaprazole Sodium is a new generation of proton pump inhibitors (“PPIs”) which treat ulcers quickly and efficiently by inhibiting gastric acid secretion and eradicating Helicobacter pylori. Preclinical studies have shown that the new drug covalently binds to proton pumps, thus providing substantially stronger and longer inhibitory effects than other PPI drugs currently available on the market. Therefore, it can effectively treat various gastric acid diseases，and is safer and possess the properties of rapid onset, stronger and longer duration of acid inhibition.